key: cord-0689982-ffoi41wd authors: Maeda, Toshiki; Sasaki, Hidenori; Togawa, Atsushi; Tanaka, Toshihiro; Arima, Hisatomi; Takata, Tohru; Takamatsu, Yasushi title: Surveillance of the current situation regarding influenza vaccination according to medical oncologists in Japan date: 2020-12-07 journal: Cancer Sci DOI: 10.1111/cas.14742 sha: ea3e3ddcc1f4e40621153ee47b90c4618e79fc54 doc_id: 689982 cord_uid: ffoi41wd This study aimed to clarify the attitude of oncologists toward influenza vaccination and the current situation and issues regarding influenza vaccination for patients on chemotherapy in Japan. A web‐based survey of medical oncologists certified by the Japanese Society of Medical Oncology was conducted between November 1 and December 31, 2019. Of the 1369 medical oncologists who were invited to participate, 415 (30.3%) responded to our survey. The questionnaire comprised 4 sections: “oncologist characteristics,” “oncologist attitude toward influenza vaccines and the current status of influenza vaccination for cancer patients undergoing chemotherapy,” “incidence of influenza infection and associated treatment complications,” and “treatment policy for influenza infection.” In total, 153 (36.9%) physicians replied that they did not actively encourage influenza vaccination for patients undergoing chemotherapy. The primary reasons given were lack of evidence (48/153, 31.4%) and uncertainty of appropriate timing (46/153, 30.1%). There was diverse variation in the timing of vaccination and in the levels of encouragement based on the cancer location and medication type. Two hundred eighty‐three (68.2%) oncologists reported that their cancer patients had experienced influenza infection while undergoing chemotherapy, and 169 (40.7%) responded that their patients had experienced an administration delay or discontinuation of medication because of influenza infection. Our surveillance revealed some oncologists considered evidence regarding the administration of influenza vaccine to cancer patients undergoing chemotherapy (particularly the optimal timing and level of recommendation by cancer location and medication) to be lacking. It also exposed the adverse impact of influenza infection in cancer patients. Due to its aging society, Japan has experienced a shift from a higher incidence of acute illnesses such as infection to a higher incidence of chronic illnesses such as cancer and other lifestyle-related con- Japan. It is estimated that 1 in 2 people will suffer from cancer during their lifetime. 1 Since 1981, cancer has been the leading cause of death, and currently approximately 370 000 people die from cancer each year, which indicates that 1 out of 3 deaths is due to cancer. 2 For cancer patients, infection may not only spoil their quality of life (QOL) but also trigger adverse effects associated with chemotherapy. Patients with cancer are especially vulnerable to infections because of their weakened immune responses resulting from the cancer itself as well as the treatment. 3, 4 Consequently, some infections are more serious in cancer patients compared with in healthy people and can even be fatal. In addition to the physical distress caused by infections, an extra financial burden, 5 and interference with ongoing chemotherapy 6 7 A study from the USA reported that the hospitalization rate among those with cancer was higher than that of the general population and that 9% of hospitalized patients with cancer were estimated to die from influenza-related infections. 8 Therefore, influenza is considered a critical source of morbidity and mortality among cancer patients. 9 At present, influenza, unlike COVID-19, can be prevented by vaccination. According to a Cochrane systematic review, influenza vaccinations have reduced the incidence of influenza infection by approximately 60% in the general population. 10 Regarding cancer patients, 1 study conducted among patients with colorectal cancer, which is one of the most prevalent types of cancer in Japan, reported that influenza vaccination significantly decreased pneumonia development, all-cause mortality, and chemotherapy discontinuation. 11 However, the effectiveness of influenza vaccination for individuals with cancer is somewhat unclear when compared with its effectiveness for immunocompetent people because of the small sample sizes and methodological limitations of the studies conducted on this population. 3, 9, 12 Research performed outside Japan found low rates of influenza vaccination among those with cancer, stemming from uncertainty about its effectiveness, fear of side effects, and a lack of data regarding the appropriate timing for vaccine administration. 13, 14 Because patients in Japan tend to be dependent and passive, and they have few opportunities to participate in medical decision-making, 15 the physician's attitude toward influenza vaccination is very likely to influence their patient's behavior. To date, few studies have systematically surveyed medical oncologists' attitudes toward influenza vaccination and the current situation and issues related to influenza vaccination for cancer patients undergoing chemotherapy. The aim of the present study was to clarify the attitude of oncologists in Japan toward influenza vaccination for cancer patients and the current situation and issues of influenza vaccination for cancer patients undergoing chemotherapy by conducting a web-based surveillance of medical oncologists in Japan. The findings of this work may provide direction for future research aimed at improving the QOL of cancer patients. The survey was created by a team comprised 3 board-certificated physicians who specialize in medical oncology, 2 board-certificated physicians who specialize in infectious diseases, and 1 epidemiology expert. The questionnaire comprised 27 questions, split into the following 4 sections: "oncologist characteristics," "oncologist attitude toward influenza vaccines and the current situation of influenza vaccination for cancer patients undergoing chemotherapy," "incidence of influenza infection and associated treatment complications," and "treatment policy for influenza infection." The "oncologist characteristics" section comprised questions regarding the oncologist's sex, age, number of years practicing oncology (<5, 5-9, 10-19, or ≥ 20 years), specialty (internist, surgeon, pediatrics, or other), annual total number of cancer patients undergoing outpatient chemotherapy at their institution (<2000, 2000-4999, 5000-9999, or ≥10 000 patients/year), and type of cancer on which they mainly conduct chemotherapy (brain, head, and neck, lung, breast, gastrointestinal, genitourinary, gynecologic, skin, hematology, bone and soft tissue, or pediatric). The "oncologist attitude toward influenza vaccines and the current situation of influenza vaccination for cancer patients undergoing chemotherapy" section comprised questions regarding the degree of recommendation for influenza vaccinations and the corresponding reasons, vaccination timing, the effects of cancer and medication type on their recommendation for influenza vaccination, number of vaccine administrations (1 or 2 shots), and family member vaccination. The "incidence of influenza infection and associated treatment complications" section comprised questions regarding their experiences of influenza infection, infection-related death, and chemotherapy discontinuation among their cancer patients over the past year, their treatment strategy, and how they manage and collect information from their patients with influenza. The "treatment policy for influenza infection" section comprised questions regarding the attitude of medical oncologists toward antiinfluenza drug use and the associated reasons and the drug they use most often for anti-influenza treatment. The results of the questionnaire were transferred into Excel format, and Excel and STATA release 16 (STATA Corp, College Station, TX, USA) were used to calculate and summarize the data. The number in each response category was divided by the number of valid responses to obtain the frequency. We also obtained 95% confidence intervals for the responses to key questions and the associated reasons. We distributed the questionnaire to 1369 medical oncologists and received responses from 415 (30.3%). everyone," 143 (34.5%) replied with "I support it if the patient asks," and 10 (2.4%) replied with "I do not actively recommend it" ( Table 2) . Among the 241 responding medical oncologists who answered "I recommend it to almost everyone," 214 respondents (88.8%) reported that they did so "to prevent influenza infection from getting worse" and 104 respondents (43.2%) reported that they did so "to prevent the onset of influenza infection." Among the 153 responding medical oncologists who answered with "I support it if the patient asks" or "I do not actively recommend it," 48 (31.4%) and 46 (30.1%) reported that they did not proactively encourage vaccination because of "lack of evidence" and "uncertainty of appropriate timing," respectively (Table 3) . "When is the appropriate timing for receiving the influenza vaccine?" We asked the 384 oncologists who claimed "I recommend it to almost everyone" or "I support it if the patient asks" about the appropriate timing of influenza vaccine administration. Among them, 157 (40.9%) answered with "I do not particularly care about timing," 94 (24.5%) answered with "between chemotherapy treatments (after chemotherapy has been discontinued)," and 82 (21.4%) answered with "during chemotherapy" ( Table 2 ). In the freeform answers, an opinion such as "any time other than during the bone marrow suppression phase" was frequently found. We also asked the 384 medical oncologists who claimed "I recommend it to almost everyone" or "I support it if the patient asks" about the number of influenza vaccine administrations they recommend. Almost all of them (362 [94.3%]) responded that they recommended just 1 shot (Table 2) . In the freeform answers, responses along the lines of "I discourage influenza vaccination during chemotherapy with corticosteroids and rituximab" were frequently found (Table 5) . "Do you also recommend patient family members to get vaccinated against influenza?" In response to the above question, 204 oncologists (54.0%) answered positively ("I recommend it to almost everyone" or "I sometimes recommend it"), whereas 168 (40.5%) answered negatively ("I do not recommend it very much," "I rarely recommended it," or "I never recommend it" ( Table 2 ). 3.3.1 | "Have you experienced any patients suffering from influenza in the last year?" and "have you experienced cases in which influenza infection caused a delay or discontinuation of chemotherapy in the last year?" Of the 415 responding medical oncologists who answered the question "have you experienced any patients suffering from influenza in the last year?", 283 (68.2%) answered with "yes" ( Table 2 ). In addition, 169 (40.7%) physicians reported experiencing a delay or discontinuation of chemotherapy in their patients because of influenza infection. When is the appropriate timing for receiving the influenza vaccine? (subjects: those who answered with "I recommend it to almost everyone" or "I support it if the patient asks" (N = 384)) Between chemotherapy treatments (after chemotherapy has been discontinued) Note: Physicians who answered with "other" or provided no response were excluded from the table; consequently, the total percentage is not always 100%. as anti-influenza drugs. When we asked the 34 physicians who answered with "I prescribe anti-influenza drugs if the patient asks," or "I do not prescribe anti-influenza drugs as much as possible" for reason they did not proactively prescribe anti-influenza drugs to their patients, the most common replies were the low efficacy of the drugs (9 [28.1%]) and a lack of evidence (9 [28.1%]) ( Table 6 ). The present study conducted a questionnaire survey to clarify the current situation and issues relating to influenza vaccination among patients undergoing chemotherapy in Japan. We found that many of the responding medical oncologists recommend their patients to get an influenza vaccine while undergoing chemotherapy. The reason they provided for recommending influenza vaccination was to prevent infec- Note: Physicians who answered with "other" or provided no response were excluded from the table; consequently, the total percentage is not always 100%. Cancer type for which influenza vaccination is not recommended (subjects: those who answered yes when asked "Do you change your degree of recommendation for influenza vaccination depending on the patient's cancer type?" (N = 74)) (multiple answers were allowed) Brain tumor A systematic review by Demicheli et al found that the incidence of influenza infection was reduced by approximately 60% in healthy people who were vaccinated against influenza virus. 10 Due to comorbidities, such as malignancy, or medications, including chemotherapy, immunocompromised persons are at relatively higher risk for experiencing medical complications from severe influenza. 16 Therefore, guidelines recommend that immunocompromised persons be vaccinated against influenza. 16 Note: Physicians who answered with "other" or provided no response were excluded from the table; consequently, the total percentage is not always 100%. Note: Physicians who answered with "other" or provided no response were excluded from the table; consequently, the total percentage is not always 100%. Rationale for using or not using antiviral drugs to treat influenza infection in cancer patients Reasons oncologists proactively prescribe anti-influenza drugs (subjects: those who answered with "I prescribe anti-influenza drugs proactively" (N = 339)) Reasons oncologists do not proactively prescribe anti-influenza drugs (subjects: those who answered with "I prescribe antiinfluenza drugs if the patient asks" or "I do not prescribe antiinfluenza drugs as much as possible" (N = 32)) Low expectation for an effect 9 28.1 (12.6-43.7) There is no evidence Note: Physicians who answered with "other" or provided no response were excluded from the table; consequently, the total percentage is not always 100%. regimens, and vaccination timing were not specified. 12 Therefore, although the available data suggest that influenza vaccination among cancer patients undergoing chemotherapy may have some positive effect, the evidence on its effectiveness is still insufficient. The present study demonstrates that approximately 40% of medical oncologists do not actively encourage vaccination, in part because of uncertainty regarding the effectiveness of influenza vaccination in cancer patients. It usually takes c. 2 wk for specific antibodies to emerge after inoculation with an influenza vaccine. 20 The optimal timing of influenza vaccine administration is controversial, and there are various opinions regarding the appropriate timing of vaccination during chemotherapy. Some studies have reported that the efficacy of influenza vaccination in particular subsets of cancer patients, such as those with lung cancer 28 or breast cancer, 22, 29 is equivalent to that in healthy people. In contrast, other studies have shown that the response to influenza vaccination is poor in patients with a hematologic malignancy such as multiple myeloma (MM) or non-Hodgkin lymphoma. 12, 25, 26, 30 The present work found that approximately 20% of medical oncologists do not recommend influenza vaccination to patients with a hematologic malignancy, specifically malignant lymphoma (ML), acute leukemia, or MM. As stated above, the effectiveness of influenza vaccination in cancer patients, especially those with a hematologic malignancy, is controversial. Further studies are needed to determine the most effective management for cancer patients, especially those with a hematologic malignancy, regarding potential influenza infection. This study revealed that some medical oncologists do not endorse influenza vaccination for patients who are undergoing treatment with corticosteroids, rituximab, or immune checkpoint inhibitors. Almost all the responding medical oncologists who support influenza vaccination of cancer patients indicated that they recommended their patients have a single administration of influenza vaccine. The main strength of this study is that we surveyed medical oncologists throughout Japan and asked them comprehensively about their current situation. We examined the attitude of physicians could be useful. 12 In Japan, insurance claim data, which has long been used for payment, has recently become available for research. It contains information on the type of medication and day of its administration, hence a more detailed study could be possible if the claim data were linked to vaccination history. However, information on vaccination is not currently available. To improve the QOL of cancer patients, the disclosure of vaccine information for enabling further detailed study in Japan is desirable. We conducted a national surveillance of medical oncologists in Japan using a web-based questionnaire to clarify the current situ- There is no conflict of interest to be declared. Toshiki Maeda https://orcid.org/0000-0002-5634-9792 CANCER STATISTICS IN JAPAN '18 Health Labour and Welfare Statistic Association Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses Evaluating the direct economic burden of health care-associated infections among patients with colorectal cancer surgery in China Influenza in children and young adults with cancer. 20 cases Epidemiology and outcomes of serious influenza-related infections in the cancer population Utility of influenza vaccination for oncology patients Vaccines for preventing influenza in healthy adults (Review) -Summary of findings for the main comparison Influenza vaccination in elderly patients with advanced colorectal cancer Influenza vaccine effectiveness among patients with cancer: A population-based study using health administrative and laboratory testing data from Ontario, Canada Low influenza vaccination rate among patients receiving chemotherapy for cancer Factors associated with influenza vaccination among adult cancer patients: a case-control study Patients' preferences for involvement in treatment decision making in Japan Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices-United States, 2020-21 influenza season IDSA clinical practice guideline for vaccination of the immunocompromised host Influenza vaccination in adult patients with solid tumours treated with chemotherapy Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy Influenza immunization of adult patients with malignant diseases Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy Immunization recommendations for adults with cancer Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma The annual impact of seasonal influenza in the US: Measuring disease burden and costs Seroconversion after influenza vaccination in patients with lung cancer Humoral immune response after vaccination against influenza in patients with breast cancer Antibody response to influenza immunization in adult patients with malignant disease Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis: Safety and immunogenicity Immunization of patients with rheumatoid arthritis against influenza: A study of vaccine safety and immunogenicity Specific antibody response after influenza immunization in systemic lupus erythematosus Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: A randomised study Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events Antibody response after influenza vaccination in HIV-infected individuals: A consecutive 3-year study The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine Effectiveness of Oseltamivir in preventing How I treat influenza in patients with hematologic malignancies Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts Surveillance of the current situation regarding influenza vaccination according to medical oncologists in Japan